Licensing deal brings Amprion’s misfolded-protein test closer to European trial sites, aiming to speed up neurodegenerative drug development.
Long before a patient ever shows a tremor, Parkinson’s disease may already be rewriting the biology of their brain. That gap, between when the disease actually starts and when doctors can currently detect it, is one of the biggest obstacles to developing drugs that treat neurodegeneration early, when they might actually work.
Amprion, a San Diego-based diagnostics company, has spent years trying to close that gap. Recently, it took a significant step toward doing so on a continental scale.
The company announced a strategic licensing collaboration with MLM Medical Labs, a central and specialty laboratory group with operations across Germany, the US and South Africa. Under the agreement, MLM will validate and run Amprion’s proprietary seed amplification assay (SAA) methodology in-house at its German lab, making the test available to biopharma sponsors running clinical trials across Europe [1].
Amprion’s test, SAAmplify-αSYN, looks for misfolded α-synuclein, a protein that clumps together abnormally in conditions like Parkinson’s disease, Lewy body dementia, multiple system atrophy and some forms of Alzheimer’s with Lewy body involvement. It’s currently the only commercially available test of its kind that can detect these misfolded protein aggregates in cerebrospinal fluid, offering a window into disease biology that symptoms alone can’t provide.
The test isn’t brand new. The FDA granted it Breakthrough Device Designation in 2019 for aiding Parkinson’s diagnosis, and it’s been commercially available in the US since 2021, previously under the name SYNTap. What’s changing now is geographic reach: rather than shipping samples across the Atlantic, European trial sponsors will soon be able to access the same underlying science through a lab on their own continent.
Russ Lebovitz, Amprion’s CEO and co-founder, framed the expansion as a response to demand that already exists.
“Neurodegenerative research is global, and access to pathology-based testing should be too,” Lebovitz said. “The demand for seed amplification testing from European researchers and biopharma sponsors is already strong. This collaboration will help identify the right patients for trials and produce richer data as we all work to better understand and treat neurodegenerative disease.”
That last point, identifying the right patients, is a bigger deal in drug development than it might sound. Trials for neurodegenerative diseases have historically struggled to enroll people who actually have the underlying biology researchers are targeting, since diagnosis by symptoms alone is often imprecise, especially in early stages. A biomarker test that can confirm misfolded protein presence before symptoms fully develop gives trial sponsors a much sharper tool for enrollment, and potentially better odds of proving whether an experimental drug is working.
Scott Houlton, CEO of MLM Medical Labs, described the deal in similar terms from the lab side, saying the collaboration allows the company to “bring a highly differentiated and scientifically validated assay to sponsors conducting clinical trials in Europe, while supporting globally harmonized study designs,” a nod to the fact that global drug trials run more smoothly when every site is measuring the same biology the same way.
Alongside the European expansion, Amprion has launched a new subsidiary, SAA Protein Manufacturing, LLC, dedicated to producing standardized protein substrates that these tests depend on. It’s an unglamorous but necessary piece of infrastructure: as demand for seed amplification testing grows globally, having a reliable, consistent supply chain for the raw materials becomes just as important as the diagnostic science itself.
Neurodegenerative disease is one of the clearest places where earlier detection could genuinely change outcomes, not because a cure is imminent, but because catching biological changes years before symptoms appear opens a window for intervention that current diagnostic pathways simply miss.
Every drug that eventually proves effective against Parkinson’s or related conditions will need trials capable of enrolling the right patients and measuring results precisely. Expanding access to tools like SAAmplify-αSYN doesn’t just help one company’s trial pipeline; it strengthens the broader infrastructure the entire field needs to translate longevity science into treatments that actually reach people before the damage is done.
